Sanford C. Bernstein lowered shares of Haleon (NYSE:HLN – Free Report) from an outperform rating to a market perform rating in a research note issued to investors on Wednesday morning, Marketbeat reports.
HLN has been the subject of a number of other research reports. UBS Group raised Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Morgan Stanley upped their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.95.
Get Our Latest Stock Report on HLN
Haleon Price Performance
Institutional Investors Weigh In On Haleon
Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC increased its holdings in shares of Haleon by 5.8% in the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after buying an additional 5,768,117 shares during the last quarter. Sculptor Capital LP increased its stake in Haleon by 67.8% in the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock valued at $73,407,000 after acquiring an additional 3,592,000 shares during the last quarter. Clearbridge Investments LLC raised its position in Haleon by 8.6% during the second quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock valued at $344,888,000 after purchasing an additional 3,307,009 shares in the last quarter. Wellington Management Group LLP lifted its stake in Haleon by 49.9% during the third quarter. Wellington Management Group LLP now owns 9,152,490 shares of the company’s stock worth $96,833,000 after purchasing an additional 3,046,841 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Haleon by 25.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock worth $53,791,000 after purchasing an additional 1,026,939 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.
Haleon Company Profile
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
See Also
- Five stocks we like better than Haleon
- 5 Top Rated Dividend Stocks to Consider
- Why AMD Stock Might Already Be This Year’s Best Buy
- There Are Different Types of Stock To Invest In
- 3 Promising Penny Stocks to Watch for Long-Term Gains in 2025
- 3 Small Caps With Big Return Potential
- The 3 Kings of Buybacks in 2024: Can They Do It Again?
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.